Supernus Announces FDA Approval of Qelbree® for the

First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 ...

Related Keywords

United States ,American ,Jack Khattar ,Jacka Khattar ,Timothyc Dec ,Greg Mattingly ,Peter Vozzo ,Exchange Commission ,Charles Psychiatric Associates In St ,Securities Exchange ,Drug Administration ,Supernus Pharmaceuticals ,Supernus Pharmaceuticals Inc ,Nasdaq ,Charles Psychiatric Associates ,Symptom Rating Scale ,Clinical Global Impression ,Important Safety Information ,Prescribing Information ,Boxed Warning ,Private Securities Litigation Reform Act ,Securities Exchange Act ,Senior Vice President ,Nasdaq Supn ,Nc ,